Jonathan Tolson is a seasoned medical affairs professional with over 14 years of experience in oncology and rare diseases. Currently serving as the Global Medical Evidence Lead at Bayer, Jonathan provides strategic leadership for medical evidence related to the marketed alpha particle-emitter Xofigo® in metastatic castration-resistant prostate cancer. Previously, Jonathan held the position of Senior Global Medical Scientific Director at Roche, where they led medical initiatives for the anti-PD-L1 immunotherapy atezolizumab (TECENTRIQ®) in metastatic lung cancer. Jonathan’s educational background includes a PhD in Molecular Cancer Diagnostics from the University of Tübingen, a Master of Science in Biotechnology from Nottingham Trent University, and a Bachelor of Science in Biomedical Science from the same institution.
This person is not in the org chart
This person is not in any teams
This person is not in any offices